The approval of Besponsa and re-approval of Mylotarg has injected huge excitement into the ADC field. Now with 4 approved drugs, over 65 candidates in clinical development and many more in preclinical development, ADCs are rapidly living up to their name – “magic bullets”.
Yet the narrow therapeutic index of ADCs means developing a clinically effective ADC is not without it’s challenges. There are more ADCs in clinical development than ever, continuous innovation in ADC technology and rapid advances in manufacturing processes readying for commercialisation. All this means there is a lot to be distilled at World ADC Berlin 2018.
Now in it’s 8th year, World ADC Berlin is Europe’s leading antibody-drug conjugate conference. Across three days, this comprehensive three streamed programs will cover every element of ADCs from discovery, development, manufacturing and clinical.
This is the forum ADC drug developers converge at for three days to immerse themselves in the latest ADC science to enable the development of more clinically safe and efficacious ADCs.
Use promotional code ADCR10 to receive a 10% discount off the current price – click here to register online